Gemtuzumab ozogamicin Completed Phase 3 Trials for Acute Myeloid Leukemia Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Completed | Treatment | 3 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT00927498 | A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old | |
| NCT00476541 | NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia | |
| NCT00860639 | Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk | |
| NCT00893399 | Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation | |
| NCT00136084 | Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia |
|
| NCT00962767 | Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission |